Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule Reports Second Quarter 2019 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 7, 2019-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2019. For the quarter ended June 30, 2019 , the Company reported a net loss of $9.1 million , or $0.08 per
View HTML
Toggle Summary ArQule to Participate in the BTIG Biotechnology Conference on Monday, August 12, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- ArQule, Inc. (Nasdaq:ARQL) today announced that Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will participate in the BTIG Biotechnology Conference on Monday, August 12, 2019 at The St.
View HTML
Toggle Summary ArQule to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases on August 8, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence , President and Chief Operating Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will present at the SVB Leerink Spotlight Series: Rare &
View HTML
Toggle Summary ArQule to Report Second Quarter 2019 Financial Results on August 7, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 24, 2019-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2019 before the market opens on Wednesday, August 7, 2019 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 27, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,387,500 shares at the
View HTML
Toggle Summary ArQule Announces Pricing of $90 Million Public Offering of Common Stock
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 25, 2019-- ArQule, Inc. (Nasdaq:ARQL) today announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share. ArQule has granted the underwriters a 30-day option to purchase up to
View HTML
Toggle Summary ArQule Announces Commencement of Proposed Public Offering of Common Stock
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 24, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the
View HTML
Toggle Summary ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 18, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 at 8:00 a.m.
View HTML
Toggle Summary ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference
Encouraging preliminary safety and clinical activity data confirm miransertib’s potential for treating PS and PROS patients Registrational study, MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children), expected to begin enrollment in Q3 2019 BURLINGTON, Mass. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting
-ARQ 531 demonstrates substantial anti-tumor activity and favorable safety profile -Four of six evaluable CLL patients, all with the BTK-C481S mutation, from cohort 7 (65 mg) experienced a Partial Response -Partial Response also observed in the study’s first Richter’s Transformation patient -Call
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.